Edotreotide
CAS No. : 204318-14-9
(Synonyms: DOTATOC; SDZ-SMT 487; SMT 487)
| Size | Price | Stock |
|---|---|---|
| 1mg | $75 | In-stock |
| 5mg | $200 | In-stock |
| 10mg | $300 | In-stock |
| 25mg | $540 | In-stock |
| 50mg | $810 | In-stock |
| 100mg | $1200 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-106033 |
| M.Wt: | 1421.64 |
| Formula: | C65H92N14O18S2 |
| Purity: | >98 % |
| Solubility: | H2O : 5 mg/mL (ultrasonic;warming;heat to 60°C);DMSO : 100 mg/mL (ultrasonic) |
Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as 90Y, 177Lu, and 68Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs)[1][2][3].
In Vivo:Edotreotide shows tumor response in the CA 20948 xenograft pancreatic tumor model in female BDIX rats that correlated with tumor size, with smaller tumors showing better response[1].
177Edotreotide may significantly prolong progression-free survival (PFS) in lung cancer NET and TC compared with Everolimus (HY-10218) in thymic neuroendocrine applications[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Edotreotide
- Cat. No.:
- HY-106033
- Quantity:
Your information is safe with us.